Indications |
Oral Community-acquired pneumonia Adult: 400 mg bid for 14 days.
Oral Acute bacterial exacerbation of chronic bronchitis Adult: 400 mg bid for 10 days.
Oral Pharyngitis Adult: 200 mg bid for 10 days.
Oral Tonsillitis Adult: 200 mg bid for 10 days.
Oral Uncomplicated skin and skin structure infections Adult: 200 mg bid for 10 days.
|
||||||||||||||||||||||||||||||
Contraindications |
Hypersensitivity to Cefditoren, other cephalosporins; or milk proteins. Carnitine deficiency. | ||||||||||||||||||||||||||||||
Warnings / Precautions |
Pregnancy and lactation. Patients with penicillin allergy. Avoid prolonged use as pivalate-containing compounds may cause carnitine deficiency over time; greater risk of carnitine deficiency in patients with renal impairment or decreased muscle mass. May decrease prothrombin activity especially in patients with renal or hepatic impairment, poor nutritional status, prolonged antibiotic treatment or patients previously stabilised on anticoagulant therapy. Long term use may result in development of drug-resistant bacteria, or superinfection including Clostridium difficile-associated diarrhoea and pseudomembranous colitis. | ||||||||||||||||||||||||||||||
Adverse Reactions |
Diarrhoea, nausea, headache, abdominal pain, vaginal moniliasis, dyspepsia, vomiting, haematuria, increased urine white blood cells, decreased haematocrit, increased glucose, interstitial pneumonia, acute eosinophilic pneumonia, acute renal failure, arthralgia, thrombocytopenia, erythema multiforme. Pseudomembranous colitis symptoms may occur during or after antibiotic treatment. Potentially Fatal: Hypersensitivity, anaphylaxis, Stevens-Johnson syndrome, toxic epidermal necrolysis. |
||||||||||||||||||||||||||||||
Overdose Reactions |
As with other beta-lactam antibiotics, symptoms include nausea, vomiting, epigastric distress, diarrhoea, and convulsions. May be removed by haemodialysis. | ||||||||||||||||||||||||||||||
Drug Interactions |
Reduced oral bioavailability when coadministered with antacids or H2-receptor antagonists. Probenecid may increase plasma concentration and prolong half-life of Cefditoren. May enhance anticoagulant effect of vitamin K antagonists (e.g. warfarin). See Below for More cefditoren pivoxil Drug Interactions |
||||||||||||||||||||||||||||||
Lab Interactions |
May induce positive direct Comb's test; false positive of copper reduction test for glucose in the urine. False negative result may occur in ferricyanide test. | ||||||||||||||||||||||||||||||
Mechanism of Actions |
Cefditoren is a third generation cephalosporin used for treatment of susceptible infections caused by gram-positive and gram-negative bacteria. It inhibits bacterial cell wall synthesis by binding to one or more of the penicillin-binding proteins (PBPs). Absorption: Bioavailability is increased by about 14-16% when administered after a high fat meal. Distribution: Mean Vd: About 9.3±1.6 L. Plasma protein binding: About 88% (in vitro); mainly to albumin. Metabolism: Not significantly metabolised. Hydrolysed to Cefditoren (active component) and pivalate. Excretion: Mean terminal elimination half life: About 1.6±0.4 hr. Excreted primarily into urine (as Cefditoren and pivaloylcarnitine); renal clearance reduced in patients with renal impairment. |
||||||||||||||||||||||||||||||
Storage Conditions |
Oral: Store at 25°C (77°F); excursion permitted to 15-30°C. Protect from light and moisture. | ||||||||||||||||||||||||||||||
Storage |
Oral: Store at 25°C (77°F); excursion permitted to 15-30°C. Protect from light and moisture. | ||||||||||||||||||||||||||||||
Available As |
|
Cefditoren
Post Review about Cefditoren Click here to cancel reply.
Cefditoren Containing Brands
Cefditoren is used in following diseases
Drug - Drug Interactions of Cefditoren
Latest News
- FDA approves Ruconest for treatment of hereditary angioedema
- FDA recommend against aspirin to prevent First Heart Attacks
- FDA approves Pomalyst (pomalidomide) for advanced multiple myeloma
- FDA approves three new drug treatments for type 2 diabetes
- Long-term consequences of vaginal delivery on the pelvic floor
No comments yet.